<DOC>
	<DOC>NCT00623727</DOC>
	<brief_summary>A study to assess treatment with a new formulation of recombinant factor VIII reconstituted with liposomes (BAY79-4980) to evaluate whether a once-a-week treatment is safe and can prevent bleeds in subjects with severe haemophilia A.</brief_summary>
	<brief_title>BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Males aged 12 to 70 years Subjects with severe hemophilia A (&lt; 1% factor VIII [FVIII]:C) Subjects with equal or greater than 150 exposure days (EDs) with any FVIII in total Subjects who have been ondemand treatment with a minimum of 1 relevant bleed per month or have been on secondary prophylaxis treatment with not more than a 3x/week schedule Subjects with bleeding events and/or treatments during the last 6 months prior to study entry which are documented in the subjects medical records Subjects with no measurable inhibitor activity Subjects with no history of FVIII inhibitor antibody formation Written informed consent by subject and parent / legal representative, if &lt; 18 years Subjects who are receiving primary prophylaxis Subjects on prophylaxis with documented requirements of &gt; 75 IU/kg/week Subjects with any other bleeding disease beside hemophilia A (i.e., von Willebrand disease) Subjects with abnormal renal function Subjects with elevated hepatic transaminases Subjects on treatment with immunomodulatory agents within the last 3 months prior to study entry or during the study Subjects with known hypersensitivity to the active substance, mouse or hamster protein, liposomes or polyethyleneglycol (PEG) Subjects who require any premedication for FVIII injections</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Hemophilia A</keyword>
	<keyword>FVIII disease</keyword>
	<keyword>rFVIII</keyword>
</DOC>